This international prize, established in 2002, encourages the work of promising young neurobiologists by providing support in the early stages of their careers. It is awarded annually for the most outstanding neurobiological research by a young scientist, as described in a 1,000-word essay based on research performed during the past three years.
The winner will receive US$25,000 and publication of his or her essay in Science. The essays of up to three finalists will also be published on Science Online.
Researchers who are 35 or younger are invited to apply by 15 June. The prizewinner will be selected by a committee of independent experts in the field, chaired by Science’s senior editor, Peter Stern.
The 2010 prize was won by Christopher Gregg, Postdoctoral Fellow at Harvard University for his research on maternal and paternal gene expression in the brain.
2011 Neurobiology Prize open for entries
Organised by Eppendorf and Science journal
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market